Nicodil tablet and preparation method thereof
By optimizing the composition ratio and preparation process of nicordil tablets, the problem of insufficient stability of existing nicordil tablets is solved, and higher stability and safety are achieved, ensuring the nicordil tablets. Validity.
Patent Information
- Application Number
- CN202411142513.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
The stability of existing nicordil tablets is insufficient, which affects the safety and effectiveness of their clinical applications.
10% nicordil, 1 to 3%, mannitol, 80 to 84%, carboxymethylcellulose calcium, 4 to 6%, octadecanol 0.5 to 1.5%, and calcium stearate 1.0 to 2.0% were used. Composition ratio, nicordil sheets are prepared by grinding, premixing, whole particles and tableting processes, controlling the particle size and moisture content, and optimizing the particle size and mixing parameters of mannitol.
It significantly improves the stability of nicordil tablets, ensures the safety and effectiveness of the product, improves the controllability and quality of the process, and is more stable than commercially available preparations.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to nicorandil tablets and a preparation method thereof. Background Art
[0002] Nicorandil is a class of ATP-sensitive potassium channel openers that have both nitrate-like effects and ATP-sensitive potassium channel opening effects, which can hyperpolarize vascular smooth muscle, reduce intracellular calcium levels, inhibit smooth muscle contraction, and thus dilate coronary arteries and microvessels. Nicorandil is an anti-anginal drug that can both relieve angina symptoms and improve the prognosis of coronary heart disease. It can effectively control symptoms, reduce all-cause mortality, and continuously improve prognosis. Summary of the invention
[0004] In view of this, the present invention aims to develop a nicorandil tablet with improved stability and a preparation method thereof, so as to ensure the safety and effectiveness of the clinical application of the nicorandil tablet.
[0005] In order to achieve the above technical objectives, the technical solution adopted by the present invention is as follows:
[0006] In a first aspect, the present invention provides a Nicorandil tablet, which comprises the following ingredients by weight: 10% Nicorandil, 1-3% corn starch, 80-84% mannitol, 4-6% carboxymethylcellulose calcium, 0.5-1.5% octadecyl alcohol, and 1.0-2.0% calcium stearate.
[0007] Preferably, the water content of the corn starch is less than 5%.
[0008] Preferably, the average particle size of mannitol is controlled within a range of 100 to 200 um.
[0009] Preferably, the particle size of the nicorandil is D50 no greater than 300 μm, and D90 no greater than 500 μm; more preferably, the particle size of the nicorandil is D50 no greater than 200 μm, and D90 no greater than 300 μm.
[0010] In a second aspect, the present invention provides a method for preparing the nicorandil tablets, comprising: grinding and sieving the nicorandil raw material; then premixing the raw and auxiliary materials; granulating the premixed raw and auxiliary materials and then mixing them; and finally tableting to obtain the tablets.
[0011] Preferably, the nicorandil raw material is ground and sieved through a 30-mesh sieve.
[0012] Preferably, the premixing of raw materials and auxiliary materials comprises: adding the raw materials, octadecyl alcohol, corn starch, mannitol, and carboxymethylcellulose calcium into a hopper mixer in sequence and mixing them at a speed of 8 to 15 rpm for 5 to 10 min; more preferably, the speed is 8 rpm for 10 min.
[0013] Preferably, the granulation comprises: using a granulator to mix the premixed raw materials and auxiliary materials with calcium stearate, preferably, the rotation speed is 200-500rpm, more preferably 200-300rpm; the screen is 1.0mm.
[0014] Preferably, the total mixing comprises: mixing the granulated materials with a hopper mixer at a rotation speed of 8 to 15 rpm for a mixing time of 5 to 10 min; preferably, the rotation speed is 8 rpm for 5 min.
[0015] Preferably, the control parameters of the tableting are: theoretical tablet weight 50 mg, using a 5 mm round flat bevel punch with a single-side notch, and a hardness of 20-60N.
[0016] Compared with the prior art, the present invention has the following technical effects:
[0017] (1) The Nicorandil tablets of the present invention have better stability than the commercially available preparation Sigma.
[0018] (2) The Nicorandil tablets of the present invention have simple components, stable process, controllable quality, and high product safety and effectiveness. DETAILED DESCRIPTION
[0019] In the description of the present invention, it should be noted that, if the specific conditions are not specified in the examples, the experiments were carried out according to conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially.
[0020] The present invention is further described in detail below in conjunction with specific embodiments, which are intended to explain the present invention rather than to limit it.
[0021] In the examples of the present invention, the reference preparation of Nicorandil tablets used is Sigmart, the licensee is Chugai Pharmaceutical Co., Ltd., the specification is 5 mg, and the specific information is shown in Table 1. The Nicorandil API used is a self-made product with a batch number of 230601. The preparation method is a prior art and is not described in detail here. The commercially available Nicorandil API that meets the specifications of Table 2 can also be used. The particle size test results of the API are shown in Table 3.
[0022] Table 1 Reference preparations
[0023]
[0024]
[0025] Table 2 Specifications of API
[0026]
[0027]
[0028] Table 3 Raw material particle size test results (parallel test 3 times)
[0029]
[0030] Particle size detection method: Take this product and measure it with a laser scattering particle size distribution instrument according to the particle size and particle size distribution determination method (Pharmacopoeia 2020 Edition Part IV General Rules 0982 Method 3). Adjust the instrument parameters, the dispersion pressure is 0.3Mpa, the feed speed is 4, the hopper height is 2.5mm, and the shading rate is 0.5% to 5%. Use the dry method to measure, D 50 Should not be greater than 300μm, D 90 Should not be greater than 500μm.
[0031] Example 1
[0032] This embodiment provides a Nicorandil tablet and a preparation method thereof, wherein the raw material composition, dosage, process equipment, and preparation process of the Nicorandil tablet are shown in Tables 4 to 7, respectively.
[0033] Table 4 Raw material and auxiliary material information
[0034]
[0035] Table 5 Amount of raw materials and auxiliary materials
[0036]
[0037] Table 6 Process equipment
[0038] Device Name model factory Crushing and granulating machine FZB-150 Zhejiang Xiaolun Pharmaceutical Machinery Co., Ltd. Hopper mixer HLS-100 Zhejiang Xiaolun Pharmaceutical Machinery Co., Ltd. YD-35 Intelligent Tablet Hardness Tester YD-35 Tianjin Tianda Tianfa Technology Co., Ltd. Tablet Press ZPS8 Shanghai Xinyuan Pharmaceutical Machinery Co., Ltd.
[0039] Table 7 Process
[0040]
[0041] The tablets of Example 1 were tested for the following items according to the Pharmacopoeia 2020 Edition General Rules for Preparations 0923 Tablet Friability Test Method, 0993 Bulk Density and Tap Density Determination Method and Supplementary Powder Flowability Determination Guidelines. The results are shown in Table 8:
[0042] Table 8 Results of small-scale research on process investigation
[0043]
[0044] The results in Table 8 show that the material fluidity and compressibility are good during the process.
[0045] Five samples were taken for uniformity testing. The sampling was carried out in a full transfer manner, and the sampling volume was 1 to 3 times the single-dose prescription volume. The results are shown in Table 9:
[0046] Table 9 Results of small-scale study on mixing uniformity
[0047]
[0048]
[0049] The results in Table 9 show that the uniformity of the samples meets the standard requirements.
[0050] Tablets were randomly selected for dissolution curve investigation. The media were water, pH 1.0 hydrochloric acid solution, pH 6.8 phosphate solution, and pH 4.5 acetate solution. Twelve tablets were selected for each medium. The average results are shown in Table 10:
[0051] Table 10 Results of dissolution curve of finished products
[0052]
[0053] The results in Table 10 show that the cumulative dissolution rate in 15 min in the four dissolution media reached more than 85%, and f2 was similar.
[0054] The tablets were further subjected to HPLC analysis, and the results are shown in Table 11:
[0055] Table 11HPLC full test results
[0056]
[0057]
[0058] Note: The standards for relevant substances are formulated based on the registration standards for imported drugs of Nicorandil Tablets and the relevant guidelines of ICH Q3B.
[0059] The results in Table 11 show that all test results of the small trial batch of Nicorandil Tablets meet the requirements and the process of this product is stable.
[0060] Example 2
[0061] Example 2 also determined other prescriptions and preparation processes of Nicorandil, as follows:
[0062] (1) Investigation of the dosage of octadecyl alcohol
[0063] The specification of this product is 5mg, and the tablet weight is 50mg. Octadecanol plays an important role in this product, and its dosage will affect the stability of the tablets. The dosage of octadecanol is investigated, and the dosage of mannitol is adjusted. The dosage of corn starch is designed to be 1mg / tablet (2% of the prescription), the dosage of carboxymethylcellulose calcium is 2.5mg / tablet (5% of the prescription), and the dosage of calcium stearate is 0.75mg / tablet (1.5% of the prescription). The dosage of octadecanol is designed to be 0.5%, 1.5%, and 2.0%, respectively. The dissolution, disintegration time and influencing factors of the tablets are investigated. The design batch is 2000 tablets. The prescription design is shown in Table 12, the process is shown in Table 13, and the inspection results are shown in Tables 12-16:
[0064] Table 12 Octadecanol dosage investigation prescription design
[0065]
[0066] Table 13 Prescription process
[0067]
[0068] Table 14 Results of the investigation on the dosage of octadecyl alcohol
[0069]
[0070]
[0071] Six samples were randomly selected to measure the dissolution results for 15 minutes. The results are shown in Table 15:
[0072] Table 15 Dissolution results of octadecyl alcohol dosage
[0073]
[0074] Note: The dissolution rates at 15 min were greater than 85%, indicating that Prescription 1 and Prescription 2 were similar to the reference preparation.
[0075] Table 16 Results of the influence factors of stabilizer dosage
[0076]
[0077]
[0078] According to the above results, the dosage of octadecanol in the formulation (0.5% to 1.5%) has no significant difference in the intermediate product. When the dosage of octadecanol is 2.0%, the tableting process is sticky and the test cannot be continued. According to the results of the influencing factors of the dosage of 0.5% to 1.5%, it can be seen that the product packaging and desiccant samples are more stable, and the stability of related substances is better with the increase of the dosage of octadecanol; the dosage of the subsequent stabilizer octadecanol is selected to be 1.0%.
[0079] (2) Investigation of the dosage of calcium carboxymethylcellulose
[0080] The dosage of calcium carboxymethylcellulose will affect the disintegration of tablets, and then affect the dissolution of tablets. The dosage of calcium carboxymethylcellulose was investigated, and the dosage of mannitol was adjusted. The dosage of corn starch was designed to be 1 mg / tablet (2% of the prescription), the dosage of octadecyl alcohol was 0.5 mg / tablet (1% of the prescription), and the dosage of calcium stearate was 0.75 mg / tablet (1.5% of the prescription). The dosage of calcium carboxymethylcellulose was adjusted to 2%, 4% and 6% respectively. The impact on the quality attributes and dissolution of the intermediates was investigated, and the design batch size was 2000 tablets. The prescription design is shown in Table 17, and the process is the same as Table 13. The results of the investigation are shown in Tables 17-19:
[0081] Table 17 Carboxymethylcellulose calcium dosage investigation prescription design (mg / tablet)
[0082]
[0083] Table 18 Carboxymethylcellulose calcium dosage investigation results
[0084]
[0085]
[0086] Six samples were randomly selected to measure the dissolution results for 15 minutes. The results are shown in Table 19:
[0087] Table 19 Carboxymethylcellulose calcium dosage investigation dissolution results
[0088]
[0089] Note: The dissolution rates after 15 min are both greater than 85%, which are similar.
[0090] According to the above results, different dosages of disintegrants were investigated. There was no significant difference in the test results of the intermediates and finished products at 4% and 6% dosages. The dissolution curves of the self-made products and the reference preparations showed a dissolution rate of more than 85% in 15 minutes, which was similar to the reference preparations. The disintegration time of the finished product at 2% dosage was significantly prolonged, and the dissolution rate of the self-made products at 15 minutes was not more than 85%, which was not similar to the reference preparations. The subsequent disintegrant dosage was selected to be 4% to 6%, preferably 5.0%.
[0091] (3) Investigation of calcium stearate dosage
[0092] According to the physical and chemical properties of the raw materials, excessive lubrication caused by excessive calcium stearate will delay dissolution, and too little dosage may cause stickiness and astringency. The dosage of calcium stearate was investigated, and the dosage of mannitol was adjusted. The dosage of corn starch was designed to be 1 mg / tablet (2% of the prescription), the dosage of octadecyl alcohol was 0.5 mg / tablet (1% of the prescription), and the dosage of calcium carboxymethyl cellulose was 2.5 mg / tablet (5% of the prescription). The dosage of calcium stearate was designed to be 1.0% and 2.0%, respectively. The effects on the characteristics of the intermediates and the dissolution of the finished product were investigated. The batch size was 2000 tablets. The prescription design is shown in Table 20. The process is the same as 13. The investigation results are shown in Tables 21-22:
[0093] Table 20 Calcium stearate dosage investigation prescription design (mg / tablet)
[0094]
[0095] Table 21 Results of calcium stearate dosage investigation
[0096]
[0097]
[0098] Six samples were randomly selected to measure the dissolution results for 15 minutes. The results are shown in Table 22:
[0099] Table 22 Calcium stearate dosage dissolution results
[0100]
[0101] Note: The dissolution rates after 15 min are both greater than 85%, which are similar.
[0102] According to the above results, in the investigation of different dosages of calcium stearate (1% to 2%), there was no significant difference in the test results of the intermediates; the 15min cumulative dissolution curve of the self-made product was greater than 85%, which was similar to the reference preparation; the subsequent lubricant dosage was selected to be 1.5%.
[0103] (4) Comparative study of starch with different moisture content
[0104] According to the results of (1) to (3), the proportions of the auxiliary materials of this product are selected as follows: 1.0% of octadecyl alcohol, 5.0% of calcium carboxymethyl cellulose, and 1.5% of calcium stearate, which is the prescription 9 shown in Table 23.
[0105] This product is sensitive to moisture. The moisture content of corn starch in the formula is relatively high. The effect of starch with different moisture content on product quality is compared. The batch size is 2000 tablets. The formula design is shown in Table 23. The formula process is the same as Table 13. The investigation results are shown in Table 24:
[0106] According to the physical and chemical properties of the raw materials, this product is sensitive to moisture, which affects the stability of the preparation. The moisture content of starch in the prescription is the highest. The moisture content of corn starch in the Pharmacopoeia CP2020 shall not exceed 14.0%. According to the requirements for the excipient supplier, the moisture content can be controlled below 5%. Based on the above prescription, corn starch with different moisture content was investigated, and corn starch with moisture content below 14% and below 5% was selected to investigate the effect on the stability of the preparation:
[0107] Table 23 Starch formulation design with different water content (mg / tablet)
[0108]
[0109] Table 24 Investigation results of starch with different moisture content
[0110]
[0111]
[0112] According to the above investigation results, the stability of the bare chips and packaged samples in prescription 10 after being placed under high temperature and high humidity conditions for 30 days was significantly increased compared with prescription 9, indicating that high-moisture starch has an impact on the stability of the preparation. Finally, it was determined that this product uses low-moisture starch (≤5.0%).
[0113] (5) Investigation of different particle sizes of mannitol
[0114] This product has a large proportion of mannitol and the process is a powder mixing direct compression process, which plays a key role in the fluidity and compressibility of the prescription material. Based on the determined prescription investigated in (4), the effects of mannitol with different particle sizes on the intermediate characteristics and the quality of the finished product were further investigated. The designed batch size was 2000 tablets. The prescription design is shown in Table 25. The investigation results are shown in Tables 26 and 27:
[0115] Table 25 Investigation of different particle sizes of mannitol
[0116]
[0117]
[0118] Five samples were randomly selected to measure the dissolution results for 15 minutes. The results are shown in Table 26:
[0119] Table 26 Summary of the test results of mixing uniformity of mannitol with different particle sizes
[0120]
[0121] Table 27 Summary of test results of different particle sizes of mannitol
[0122] batch number Prescription 11 Prescription 9 Prescription 12 Angle of repose(°) 37.99 37.29 34.65 Bulk density (g / cm-3) 0.53 0.52 0.48 Tap density (g / cm-3) 0.62 0.65 0.59 Compression (%) 15 20 19. Tablet weight(g) 0.049~0.052 0.052~0.055 0.048~0.054 Sheet thickness (mm) 2.16~2.19 2.16~2.22 2.16~2.26 Pressure single value (KN) 3.0~4.0 4.5~5.5 4.2~6.3 Hardness(N) 23.3~37.5 30.1~37.7 21.4~40.6 Weight difference (%) -4.23~+2.69 -5.5~+1.8 -6.2~+3.2 Friability (%) 0.34 0.18 0.57 (tablet surface is not smooth) Disintegration time 1min19s~1min44s 58s~1min48s 1min39s~1min54s
[0123] According to the above research results, the mixing uniformity results of mannitol with different particle sizes meet the requirements when the particle size is 100-200um, but do not meet the requirements when the particle size is 300um. The fluidity and compressibility of the material are good. There is no significant difference in the results of the plain tablets when the mannitol particle size is 100-200um. When the particle size is 300um, the surface of the tablet becomes uneven after being brittle. Therefore, it is more appropriate to control the average particle size of mannitol to 100-200um.
[0124] (6) Investigation of mixing parameters
[0125] This product is a powder direct tableting process. The premixing and total mixing parameters have a great influence on the content and mixing uniformity of the product. In order to determine the best mixing parameters and ensure the uniformity of the content during the process, the premixing and total mixing time are studied respectively to examine the impact on the intermediate content and mixing uniformity. The design batch is 2000 tablets. The prescription is the same as Table 23, the process is shown in Table 28, and the results are shown in Table 30:
[0126] Table 28 Mixing parameters for investigation of process
[0127] Process steps Preparation process Premix The mixing speed was 8 rpm and the mixing time was 10 min (samples were taken at 5 and 10 min to check the mixing uniformity). Total Mix The mixing speed was 8 rpm and the mixing time was 10 min (samples were taken at 5 and 10 min to check the mixing uniformity).
[0128] Table 29 Mixing uniformity inspection results
[0129]
[0130] According to the above results, the mixing uniformity of premixing and total mixing at different mixing time periods meets the requirements; the premixing and total mixing time can both be determined to be 5-10 minutes.
[0131] (7) Tablet hardness test
[0132] The hardness of tablets has an important influence on the characteristics of the preparation. Too high a hardness is not conducive to disintegration and dissolution, while too low a hardness will increase brittleness. Therefore, during the tableting process, the characteristics of tablets with different hardness should be examined to provide a basis for the setting of pilot and large-scale production process parameters. The design batch size is 2,000 tablets. Now select a batch of tablets with a particle compression of less than 20N and a hardness of 20 to 60N, as shown in Table 30 below:
[0133] Table 30 Tablet hardness test results
[0134] batch number Prescription 14 Prescription 15 Inspection item (hardness) 10~20N 20~60N Tablet weight(g) 0.0550~0.0556 0.0547~0.0566 Sheet thickness (mm) 2.14~2.21 2.16~2.22 Pressure single value (KN) 1.5~2.5 4.5~5.5 Hardness(N) 16.2~19.6 30.1~37.7 Weight difference (%) -2.8~2.6 -5.5~1.8 Friability (%) 0.37 (tablet surface is not smooth) 0.18 Disintegration time 53s~1min56s 58s~1min48s
[0135] According to the above results, all test results of the intermediates meet the requirements, but the tablets with low hardness have uneven surfaces after being crushed. The tablet hardness is tentatively set at 20-60N.
[0136] Example 3
[0137] Comparative Example 1, the existing Sigmart and the tablets of Example 1 in CN115429763 were investigated for stability. The results are shown in Table 31 below:
[0138] Table 31 Stability test results
[0139]
[0140]
[0141] By comparison, the result of Example 1 is obviously better than Sigmart under high temperature conditions, and is obviously better than Example 1 in CN115429763 under high humidity conditions.
[0142] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A Nicorandil tablet, characterized in that: The composition according to weight percentage is: 10% nicorandil, 1-3% corn starch, 80-84% mannitol, 4-6% carboxymethyl cellulose calcium, 0.5-1.5% octadecyl alcohol, and 1.0-2.0% calcium stearate.
2. The Nicorandil tablet according to claim 1, characterized in that: The water content of the corn starch is less than 5%.
3. The Nicorandil tablet according to claim 1 or 2, characterized in that: The mannitol average particle size control range is 100 to 200 um.
4. The Nicorandil tablet according to claim 1, characterized in that: The particle size of Nicorandil is D 50 Not more than 300μm, D 90 Preferably, the particle size of Nicorandil is D 50 Not more than 200μm, D 90 Not more than 300μm.
5. The method for preparing the Nicorandil tablets according to any one of claims 1 to 4, characterized in that: include: The Nicorandil raw material is ground into powder and sieved; then the raw and auxiliary materials are premixed; the premixed raw and auxiliary materials are granulated and then mixed; finally, tableting is performed to obtain the product.
6. The preparation method according to claim 5, characterized in that: The nicorandil raw material is ground into powder and sieved through a 30-mesh sieve.
7. The preparation method according to claim 5, characterized in that: The premixing of raw materials and auxiliary materials comprises: adding raw materials, octadecyl alcohol, corn starch, mannitol, and carboxymethylcellulose calcium into a hopper mixer in sequence, mixing at a rotation speed of 8 to 15 rpm and a mixing time of 5 to 10 minutes; more preferably, the rotation speed is 8 rpm and the mixing time is 10 minutes.
8. The preparation method according to claim 5, characterized in that: The granulation comprises: using a granulator to mix the premixed raw materials and auxiliary materials with calcium stearate, preferably, the rotation speed is 200-500rpm, more preferably 200-300rpm; the screen is 1.0mm.
9. The preparation method according to claim 5, characterized in that: The total mixing comprises: mixing the granulated materials with a hopper mixer at a rotation speed of 8 to 15 rpm for a mixing time of 5 to 10 min; preferably, the rotation speed is 8 rpm for a mixing time of 5 min.
10. The preparation method according to claim 5, characterized in that: The control parameters of the tableting are: theoretical tablet weight 50 mg, a 5 mm round flat bevel punch with a single-side notch, and a hardness of 20-60N.
Citation Information
Patent Citations
Preparation method of stable Nicodil preparation
CN115282123A
Nicodil tablet and preparation method thereof
CN115429763A
